Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Settles with LumiCyte, Molecular Analytical Systems over SELDI

NEW YORK, May 30 - Ciphergen Biosystems, LumiCyte, and Molecular Analytical Systems have settled their lawsuit over a mass spectrometry technology called SELDI-TOF, Ciphergen said yesterday.

 

Under the terms of the settlement, Ciphergen will pay revenue-based royalties of up to $10 million, over a 10-year period, to Molecular Analytical Systems. Ciphergen will also issue about 1.25 million shares to LumiCyte and pay the company about $3 million in cash.

 

In return, Ciphergen acquires Molecular Analytical's exclusive worldwide patent rights to surface enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS). Molecular Analytical licenses patents protecting the technology from Baylor College of Medicine. Moreover, LumiCyte has assigned all its rights relating to the technology, which it acquired from Molecular Analytical, to Ciphergen without restrictions.

 

For further information, see the company statement.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.